Cargando…

CD81 is a novel immunotherapeutic target for B cell lymphoma

The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vences-Catalán, Felipe, Kuo, Chiung-Chi, Rajapaksa, Ranjani, Duault, Caroline, Andor, Noemi, Czerwinski, Debra K., Levy, Ronald, Levy, Shoshana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605745/ https://www.ncbi.nlm.nih.gov/pubmed/31123084 http://dx.doi.org/10.1084/jem.20190186

Ejemplares similares

CD81 costimulation skews CAR transduction toward naive T cells
por: Schultz, Liora M., et al.
Publicado: (2022)

Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis
por: Vences-Catalán, Felipe, et al.
Publicado: (2018)

CD81 and Hepatitis C Virus (HCV) Infection
por: Fénéant, Lucie, et al.
Publicado: (2014)

CD81 association with SAMHD1 enhances HIV-1 reverse transcription by increasing dNTP levels
por: Rocha-Perugini, Vera, et al.
Publicado: (2017)

Normal Lymphocyte Development but Delayed Humoral Immune Response in CD81-null Mice
por: Maecker, Holden T., et al.
Publicado: (1997)

CD81 as target for B cell lymphomas
por: Küppers, Ralf
Publicado: (2019)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
por: Rocha-Perugini, Vera, et al.
Publicado: (2008)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: Putative CD81 binding region 1 is not involved in CD81 binding
por: Rothwangl, Katharina B, et al.
Publicado: (2008)

Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021)

Biological role of NK cells and immunotherapeutic approaches in breast cancer
por: Roberti, María P., et al.
Publicado: (2012)

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
por: Poggio, Teresa, et al.
Publicado: (2018)

The developmental regulation of CD81 in the rat retina
por: Pan, Ye, et al.
Publicado: (2007)

CD82 and Gangliosides Tune CD81 Membrane Behavior
por: Fernandez, Laurent, et al.
Publicado: (2021)

Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma
por: Dias, Joana N. R., et al.
Publicado: (2021)

Cd81 Interacts with the T Cell Receptor to Suppress Signaling
por: Cevik, Safak Isil, et al.
Publicado: (2012)

Tetraspanin CD81 regulates HSV-1 infection
por: Benayas, Beatriz, et al.
Publicado: (2020)

Elderly CD8(+) T cells in the focus for immunotherapeutic approaches
por: Lis, Annette, et al.
Publicado: (2023)

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
por: Shree, Tanaya, et al.
Publicado: (2021)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma
por: Liu, Bai, et al.
Publicado: (2014)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes
por: Takeda, Yoshito, et al.
Publicado: (2003)

CD9 and CD81 Interactions and Their Structural Modelling in Sperm Prior to Fertilization
por: Frolikova, Michaela, et al.
Publicado: (2018)

Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis
por: Chen, Fang, et al.
Publicado: (2018)

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020)

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
por: Choe, Deborah, et al.
Publicado: (2023)

Dual Function of CD81 in Influenza Virus Uncoating and Budding
por: He, Jiang, et al.
Publicado: (2013)

The Association of CD81 Polymorphisms with Alloimmunization in Sickle Cell Disease
por: Tatari-Calderone, Zohreh, et al.
Publicado: (2013)

CD81 marks immature and dedifferentiated pancreatic β-cells
por: Salinno, Ciro, et al.
Publicado: (2021)

Pax5 mediates the transcriptional activation of the CD81 gene
por: Hosokawa, Kohei, et al.
Publicado: (2021)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
por: Zhang, Keying, et al.
Publicado: (2021)

An engineered CD81‐based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles
por: Vogt, Stefan, et al.
Publicado: (2021)

Looking Forward to Ochsner's 81st Year
por: Amedee, Ronald G.
Publicado: (2022)

Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
por: Al Olaby, Reem R., et al.
Publicado: (2014)

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
por: Amano, M, et al.
Publicado: (2014)

Human Vaccines & Immunotherapeutics: News May 2022
por: Ellis, Ronald, et al.
Publicado: (2022)

Human vaccines & immunotherapeutics: News October 2022
por: Ellis, Ronald, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u63ri8qme2icdo4b6fre5vp39c